New weight-loss drug offers relief for knee arthritis pain

2–3 minutes

reading time

International research, involving Kolling Institute investigators, has found a new generation weight loss medication offers significant relief for people living with knee osteoarthritis and obesity.

The findings, published in the prestigious New England Journal of Medicine, followed two large-scale clinical trials involving more than a thousand people.

They found that the medication retatrutide offered substantial improvements in knee pain, physical function and body weight, and could offer an important new treatment option for people living with painful knee osteoarthritis and obesity.

Leading rheumatologist and Kolling Institute researcher Professor David Hunter co-authored the research, and says the results are encouraging.

“Osteoarthritis is one of the leading causes of pain and disability worldwide, yet our current treatment options remain limited. These findings suggest we may be entering a new era in how we manage this common and debilitating condition.”

As part of the trials, participants received weekly injections of retatrutide or placebo for 68 to 80 weeks. Retatrutide is an investigational medication that acts on three hormone receptors involved in appetite and metabolism: GLP-1, GIP and glucagon.

The researchers found that:

  • Nearly 70% of participants receiving the 9 mg dose achieved at least a 50% reduction in knee pain, compared with approximately 38% receiving placebo.
  • Weight loss reached approximately 25% at the highest dose, compared with approximately 5% in placebo groups.
  • Physical function improved substantially, with approximately 64% of participants achieving at least a 50% improvement, compared with 33% receiving placebo.
  • Significant improvements in knee pain were observed across both trials

Professor Hunter welcomed the findings.

“For many people with knee osteoarthritis, pain interferes with walking, exercising, working and participating in everyday activities. An intervention that produces meaningful improvements in both pain and mobility could make a substantial difference to their quality of life.”

Could weight-loss medications change how we treat osteoarthritis?

Professor Hunter said the findings reinforce the importance of addressing obesity as part of comprehensive osteoarthritis care.

“We have traditionally approached osteoarthritis primarily as a problem of the joint itself. These findings highlight the importance of considering the whole person, including metabolic health and excess body weight.

“Reducing weight can substantially decrease the forces transmitted through the knee, while improvements in metabolic health may provide additional benefits. We still need to understand how much of the pain relief is directly attributable to weight loss and whether other mechanisms are involved.”

The results also raise important questions about whether treatments such as retatrutide could eventually reduce the need for knee replacement surgery.

“One of the most exciting possibilities is whether effective treatment of obesity and knee pain might help people delay or avoid joint replacement,” Professor Hunter said.

Researchers from across Australia, Europe and North America were involved in the clinical research.

By: Kolling Institute

Posted on: 

NSWGOV logo